TTRX Turn Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2023016 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-236.5%
TTM EPS YoY-186.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-412.3%
ROA-123.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets65.2%
Debt / equity1.09x
Current ratio3.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-72.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $605,197 | $475,064 | $109,434 | $34,934 | $158,699 | $62,678 | $9,259 | $9,766 |
| SG&A expense | $1.38M | $1.15M | $1.14M | $2.16M | $1.75M | $1.30M | $375,738 | $319,191 |
| Operating income | -$1.98M | -$1.63M | -$1.25M | -$2.19M | -$1.91M | -$1.37M | -$384,997 | -$328,957 |
| Interest expense | $341,208 | — | — | — | — | — | — | — |
| Net income | -$6.23M | -$5.85M | -$970,972 | $279,070 | -$1.90M | -$1.24M | -$328,547 | -$323,130 |
| EPS (basic) | -0.21 | -0.20 | -0.03 | — | -0.07 | -0.05 | -0.01 | — |
| EPS (diluted) | -0.21 | -0.20 | -0.03 | — | -0.07 | -0.05 | -0.01 | — |
| Weighted avg. shares (diluted) | 30.14M | 29.79M | 29.48M | — | 27.98M | 27.49M | 26.96M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.43M | $9.95M | $11.01M | $4.03M | $3.11M | $3.19M | $1.57M | $872,599 |
| Current assets | $11.08M | $10.43M | $11.45M | $5.20M | $3.29M | — | — | $1.10M |
| Intangibles | $912,673 | $911,219 | $919,947 | $922,171 | $904,885 | — | — | $821,931 |
| Total assets | $16.35M | $16.96M | $18.64M | $12.16M | $4.30M | — | — | $2.05M |
| Current liabilities | $3.48M | $8.76M | $5.13M | $6.00M | $2.31M | — | — | $707,932 |
| Short-term debt | $444,204 | — | — | — | — | — | — | — |
| Long-term debt | $5.74M | $6.06M | $5.94M | — | — | — | — | — |
| Total debt | $6.19M | $6.06M | $5.94M | — | — | — | — | — |
| Total liabilities | $10.66M | $16.27M | $12.53M | $7.48M | $3.79M | — | — | $2.23M |
| Shareholders' equity | $5.69M | $686,888 | $6.12M | $4.69M | $504,013 | $1.77M | $818,710 | -$177,432 |
| Net debt | -$3.25M | -$3.89M | -$5.07M | — | — | — | — | — |
| Shares outstanding | 30.53M | 29.79M | 29.79M | 29.45M | 28.02M | — | — | 26.85M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.55M | -$923,364 | -$1.63M | -$1.18M | -$588,610 | -$499,966 | -$298,058 | -$430,545 |
| Investing cash flow | -$16,140 | -$5,798 | -$12,227 | -$31,441 | -$89,794 | — | — | -$7,842 |
| Financing cash flow | $1.64M | $1 | $7.79M | $3.18M | $594,617 | $2.15M | $998,092 | $522,206 |
| Stock-based compensation | $713,205 | $419,233 | $280,830 | $256,380 | $39,084 | $47,184 | $76,597 | $37,813 |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.